8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 2, 2026·SEC
Apellis Pharmaceuticals, Inc.(APLS)Earnings, Financials & Key Ratios
APLS•NASDAQ
$41.12
$5.26B mkt cap·228.4× P/E·Price updated May 6, 2026
AboutApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.Show more
- Revenue$1B+28.5%
- EBITDA$57M+134.9%
- Net Income$22M+111.3%
- EPS (Diluted)0.18+111.3%
- Gross Margin89.81%+5.7%
- EBITDA Margin5.68%+127.2%
- Operating Margin5.52%+126.2%
- Net Margin2.23%+108.8%
- ROE7.48%+108.0%
- ROIC12.3%+112.0%
- Debt/Equity1.31-36.1%
- Interest Coverage1.54+139.9%
APLS Key Insights
Apellis Pharmaceuticals, Inc. (APLS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓Momentum leader: RS Rating 93 (top 7%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 32.0%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Expensive at 14.0x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
APLS Price & Volume
Apellis Pharmaceuticals, Inc. (APLS) stock price & volume — 10-year historical chart
Loading chart...
APLS Growth Metrics
Apellis Pharmaceuticals, Inc. (APLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years31.98%
3 Years136.98%
TTM28.46%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM111.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM110.69%
Return on Capital
10 Years-63.09%
5 Years-53.31%
3 Years-36.73%
Last Year7.64%
APLS Recent Earnings
Apellis Pharmaceuticals, Inc. (APLS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 9/12 qtrs (75%)
Q1 2026Latest
Feb 24, 2026EPS
$0.47
Est $0.39
-20.5%
Revenue
$200M
Est $199M
+0.3%
Q4 2025
Oct 30, 2025EPS
$1.67
Est $1.03
+62.1%
Revenue
$459M
Est $199M
+130.1%
Q3 2025
Jul 31, 2025EPS
$0.33
Est $0.44
+25.0%
Revenue
$178M
Est $372M
-52.0%
Q2 2025
May 7, 2025EPS
$0.74
Est $0.36
-105.6%
Revenue
$167M
Est $209M
-20.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $0.47vs $0.39-20.5% | $200Mvs $199M+0.3% |
| Q4 2025 | Oct 30, 2025 | $1.67vs $1.03+62.1% | $459Mvs $199M+130.1% |
| Q3 2025 | Jul 31, 2025 | $0.33vs $0.44+25.0% | $178Mvs $372M-52.0% |
| Q2 2025 | May 7, 2025 | $0.74vs $0.36-105.6% | $167Mvs $209M-20.3% |
Based on last 12 quarters of dataView full earnings history →
APLS Peer Comparison
Apellis Pharmaceuticals, Inc. (APLS) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 BCAB | 5.29M | 4.50 | -0.09 | -81.82% | -29.8% | |||
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare APLS vs Peers
Apellis Pharmaceuticals, Inc. (APLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APLS Income Statement
Apellis Pharmaceuticals, Inc. (APLS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 250.65M | 66.56M | 75.42M | 396.59M | 781.37M | 1B |
| Revenue Growth % | - | - | - | - | -73.44% | 13.31% | 425.83% | 97.02% | 28.46% |
| Cost of Goods Sold | 0 | 127.92M | 595.45K | 25.05M | 5.2M | 5.64M | 58.51M | 117.72M | 102.24M |
| COGS % of Revenue | - | - | - | 9.99% | 7.81% | 7.47% | 14.75% | 15.07% | 10.19% |
| Gross Profit | -50.77M▲ 0% | -127.92M▼ 152.0% | -595.45K▲ 99.5% | 225.6M▲ 37986.7% | 61.36M▼ 72.8% | 69.79M▲ 13.7% | 338.08M▲ 384.5% | 663.64M▲ 96.3% | 901.55M▲ 35.8% |
| Gross Margin % | - | - | - | 90.01% | 92.19% | 92.53% | 85.25% | 84.93% | 89.81% |
| Gross Profit Growth % | - | -151.98% | 99.53% | 37986.7% | -72.8% | 13.73% | 384.45% | 96.3% | 35.85% |
| Operating Expenses | 50.77M | 127.92M | 287.42M | 439.32M | 597.64M | 664.4M | 855.2M | 828.62M | 846.12M |
| OpEx % of Revenue | - | - | - | 175.28% | 897.86% | 880.91% | 215.64% | 106.05% | 84.29% |
| Selling, General & Admin | 10.46M | 22.64M | 66.45M | 139.4M | 176.77M | 277.16M | 500.81M | 501.05M | 550.26M |
| SG&A % of Revenue | - | - | - | 55.62% | 265.57% | 367.48% | 126.28% | 64.13% | 54.82% |
| Research & Development | 40.3M | 105.29M | 220.97M | 299.92M | 420.87M | 387.24M | 354.39M | 327.57M | 295.85M |
| R&D % of Revenue | - | - | - | 119.66% | 632.29% | 513.43% | 89.36% | 41.92% | 29.47% |
| Other Operating Expenses | 11.54K | -111K | 0 | -501K | 1.36M | -288K | 0 | 0 | 0 |
| Operating Income | -50.77M▲ 0% | -127.92M▼ 152.0% | -288.02M▼ 125.1% | -213.73M▲ 25.8% | -536.28M▼ 150.9% | -594.61M▼ 10.9% | -517.12M▲ 13.0% | -164.98M▲ 68.1% | 55.43M▲ 133.6% |
| Operating Margin % | - | - | - | -85.27% | -805.67% | -788.38% | -130.39% | -21.11% | 5.52% |
| Operating Income Growth % | -86.08% | -151.98% | -125.14% | 25.79% | -150.92% | -10.88% | 13.03% | 68.1% | 133.6% |
| EBITDA | -50.76M | 0 | -287.42M | -212.87M | -534.78M | -593.13M | -515.42M | -163.18M | 56.98M |
| EBITDA Margin % | - | - | - | -84.93% | -803.43% | -786.41% | -129.96% | -20.88% | 5.68% |
| EBITDA Growth % | - | 100% | - | 25.94% | -151.23% | -10.91% | 13.1% | 68.34% | 134.92% |
| D&A (Non-Cash Add-back) | 11.94K | 127.92M | 595.45K | 859K | 1.49M | 1.49M | 1.7M | 1.8M | 1.56M |
| EBIT | -50.91M | -124.99M | -299.42M | -313.09M | -732.76M | -618.88M | -496.92M | -156.32M | 68.44M |
| Net Interest Income | -96.92K | 447.81K | -176K | -25.77M | -12.82M | -23.71M | -8.65M | -27.62M | -31.18M |
| Interest Income | 0 | 2.96M | 5.11M | 4.16M | 418K | 8.91M | 20.93M | 12.77M | 13.14M |
| Interest Expense | 96.92K | 2.51M | 5.29M | 29.94M | 13.24M | 32.63M | 29.58M | 40.39M | 44.33M |
| Other Income/Expense | -239K | 422.81K | -16.69M | -129.3M | -209.72M | -56.89M | -9.38M | -31.74M | -31.32M |
| Pretax Income | -51.01M▲ 0% | -127.5M▼ 150.0% | -304.71M▼ 139.0% | -343.03M▼ 12.6% | -746M▼ 117.5% | -651.5M▲ 12.7% | -526.5M▲ 19.2% | -196.72M▲ 62.6% | 24.11M▲ 112.3% |
| Pretax Margin % | - | - | - | -136.86% | -1120.75% | -863.81% | -132.76% | -25.18% | 2.4% |
| Income Tax | 250.61K | -533K | 0 | 1.84M | 352K | 669K | 2.13M | 1.16M | 1.72M |
| Effective Tax Rate % | -0.49% | 0.42% | 0% | -0.54% | -0.05% | -0.1% | -0.4% | -0.59% | 7.14% |
| Net Income | -51.01M▲ 0% | -127.5M▼ 150.0% | -304.71M▼ 139.0% | -344.87M▼ 13.2% | -746.35M▼ 116.4% | -652.17M▲ 12.6% | -528.63M▲ 18.9% | -197.88M▲ 62.6% | 22.39M▲ 111.3% |
| Net Margin % | - | - | - | -137.59% | -1121.27% | -864.7% | -133.29% | -25.32% | 2.23% |
| Net Income Growth % | -88.04% | -149.97% | -138.98% | -13.18% | -116.41% | 12.62% | 18.94% | 62.57% | 111.31% |
| Net Income (Continuing) | -51.01M | -127.5M | -304.71M | -344.87M | -746.35M | -652.17M | -528.63M | -197.88M | 22.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.49▲ 0% | -2.34▼ 57.0% | -4.98▼ 112.8% | -4.59▲ 7.8% | -8.84▼ 92.6% | -6.15▲ 30.4% | -4.45▲ 27.6% | -1.60▲ 64.0% | 0.18▲ 111.3% |
| EPS Growth % | 0.67% | -57.05% | -112.82% | 7.83% | -92.59% | 30.43% | 27.64% | 64.04% | 111.25% |
| EPS (Basic) | -1.49 | -2.34 | -4.98 | -4.59 | -8.84 | -6.15 | -4.45 | -1.60 | 0.18 |
| Diluted Shares Outstanding | 34.22M | 54.4M | 62.23M | 75.16M | 84.42M | 106.11M | 118.68M | 123.91M | 126.02M |
| Basic Shares Outstanding | 34.22M | 54.4M | 62.23M | 75.16M | 84.42M | 106.11M | 118.68M | 123.91M | 126.02M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
APLS Balance Sheet
Apellis Pharmaceuticals, Inc. (APLS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 182.02M | 202.44M | 373.09M | 917.19M | 824.05M | 719.52M | 766.33M | 788.95M | 1.01B |
| Cash & Short-Term Investments | 175.64M | 176.27M | 351.99M | 877.65M | 701.23M | 551.8M | 352.3M | 416.14M | 467.76M |
| Cash Only | 175.64M | 176.27M | 351.99M | 565.78M | 640.19M | 551.8M | 351.19M | 411.29M | 467.76M |
| Short-Term Investments | 0 | 0 | 0 | 311.87M | 61.03M | 0 | 1.11M | 4.85M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 25M | 80.1M | 7.73M | 206.44M | 271.72M | 366.22M |
| Days Sales Outstanding | - | - | - | 36.41 | 439.25 | 37.39 | 190 | 126.93 | 133.17 |
| Inventory | 0 | 0 | 0 | 0 | 24M | 85.71M | 146.36M | 82.48M | 142.56M |
| Days Inventory Outstanding | - | - | - | - | 1.68K | 5.55K | 913.04 | 255.74 | 508.95 |
| Other Current Assets | 1.31M | 1.84M | 1.31M | 11.14M | 13.54M | 36.66M | 22.41M | 9.1M | 0 |
| Total Non-Current Assets | 116.15K | 1.09M | 16.15M | 43.38M | 57.72M | 40.69M | 22.4M | 96.1M | 60.42M |
| Property, Plant & Equipment | 0 | 977.92K | 15.77M | 24.52M | 26.08M | 24.89M | 21.09M | 19.04M | 19.9M |
| Fixed Asset Turnover | - | - | - | 10.22x | 2.55x | 3.03x | 18.80x | 41.05x | 50.43x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 3.24M | 0 | 0 |
| Other Non-Current Assets | 116.15K | 116.42K | 385.09K | 18.86M | 31.64M | 15.8M | -1.93M | 77.06M | 40.51M |
| Total Assets | 182.13M▲ 0% | 203.53M▲ 11.8% | 389.24M▲ 91.2% | 960.57M▲ 146.8% | 881.76M▼ 8.2% | 760.22M▼ 13.8% | 788.73M▲ 3.8% | 885.05M▲ 12.2% | 1.08B▲ 21.5% |
| Asset Turnover | - | - | - | 0.26x | 0.08x | 0.10x | 0.50x | 0.88x | 0.93x |
| Asset Growth % | 563.91% | 11.75% | 91.24% | 146.78% | -8.2% | -13.78% | 3.75% | 12.21% | 21.49% |
| Total Current Liabilities | 6.55M | 17.02M | 65.75M | 128.33M | 131.85M | 167.61M | 247.59M | 185.51M | 323.6M |
| Accounts Payable | 3.66M | 10.25M | 8.36M | 8.48M | 16.91M | 37.34M | 37.52M | 38.57M | 56.8M |
| Days Payables Outstanding | - | 29.26 | 5.12K | 123.52 | 1.19K | 2.42K | 234.03 | 119.59 | 202.78 |
| Short-Term Debt | 0 | 1.67M | 2.61M | 0 | 0 | 0 | 0 | 0 | 100.75M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 43.34M | 4.23M | 7.58M | 81.43M | 75.83M | 0 | 127.55M |
| Current Ratio | 27.77x | 11.89x | 5.67x | 7.15x | 6.25x | 4.29x | 3.10x | 4.25x | 3.14x |
| Quick Ratio | 27.77x | 11.89x | 5.67x | 7.15x | 6.07x | 3.78x | 2.50x | 3.81x | 2.70x |
| Cash Conversion Cycle | - | - | - | - | 937.19 | 3.17K | 869.01 | 263.08 | 439.34 |
| Total Non-Current Liabilities | 26.63M | 25.54M | 289.26M | 627.68M | 551.26M | 422.74M | 346.62M | 471M | 381.51M |
| Long-Term Debt | 26.39M | 25.38M | 142.57M | 358.83M | 189.02M | 92.74M | 93.03M | 452.83M | 373.61M |
| Capital Lease Obligations | 0 | 0 | 11.86M | 15.22M | 17.08M | 14.35M | 11.45M | 10.2M | 11.95M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 244.29K | 158.78K | 134.84M | 253.64M | 345.15M | 315.65M | 242.13M | 7.97M | -4.04M |
| Total Liabilities | 33.19M | 42.56M | 355.02M | 756.01M | 683.1M | 590.35M | 594.21M | 656.51M | 705.11M |
| Total Debt | 26.39M | 27.04M | 157.03M | 377.73M | 210.22M | 112.71M | 110.93M | 469.78M | 486.31M |
| Net Debt | -149.25M | -149.22M | -194.95M | -188.05M | -429.97M | -439.09M | -240.26M | 58.49M | 18.55M |
| Debt / Equity | 0.18x | 0.17x | 4.59x | 1.85x | 1.06x | 0.66x | 0.57x | 2.06x | 1.31x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 8.53x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.33x |
| Interest Coverage | -525.30x | -49.74x | -56.66x | -10.46x | -55.34x | -18.97x | -16.80x | -3.87x | 1.54x |
| Total Equity | 148.94M▲ 0% | 160.97M▲ 8.1% | 34.23M▼ 78.7% | 204.56M▲ 497.6% | 198.66M▼ 2.9% | 169.87M▼ 14.5% | 194.52M▲ 14.5% | 228.54M▲ 17.5% | 370.15M▲ 62.0% |
| Equity Growth % | 525.96% | 8.08% | -78.74% | 497.6% | -2.88% | -14.49% | 14.51% | 17.49% | 61.96% |
| Book Value per Share | 4.35 | 2.96 | 0.55 | 2.72 | 2.35 | 1.60 | 1.64 | 1.84 | 2.94 |
| Total Shareholders' Equity | 148.94M | 160.97M | 34.23M | 204.56M | 198.66M | 169.87M | 194.52M | 228.54M | 370.15M |
| Common Stock | 5.03K | 5.63K | 6.39K | 8K | 10K | 11K | 12K | 12K | 12K |
| Retained Earnings | -149.26M | -276.77M | -581.47M | -926.35M | -1.66B | -2.31B | -2.84B | -3.04B | -3.01B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -122.81K | -153.78K | -117K | -2.09M | -875K | -3.54M | -3.31M | -2.1M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
APLS Cash Flow Statement
Apellis Pharmaceuticals, Inc. (APLS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -46.6M | -131.24M | -211.13M | -160.49M | -563.13M | -513.75M | -594.74M | -87.87M | 45.33M |
| Operating CF Margin % | - | - | - | -64.03% | -846% | -681.16% | -149.96% | -11.25% | 4.52% |
| Operating CF Growth % | -79.19% | -181.66% | -60.88% | 23.99% | -250.88% | 8.77% | -15.76% | 85.23% | 151.59% |
| Net Income | -51.01M | -127.5M | -304.71M | -344.87M | -746.35M | -652.17M | -528.63M | -197.88M | 22.39M |
| Depreciation & Amortization | 11.94K | 0 | 596K | 859K | 1.49M | 1.49M | 1.7M | 1.8M | 0 |
| Stock-Based Compensation | 5.42M | 7.73M | 21.14M | 45.38M | 70.67M | 91.08M | 105.94M | 114.13M | 0 |
| Deferred Taxes | 153.69K | 0 | 0 | 0 | 198.26M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 13.56K | 568.33K | 18.52M | 118.56M | 6.33M | 61.55M | 26.41M | 12.44M | 108.06M |
| Working Capital Changes | -1.19M | -12.04M | 53.31M | 19.59M | -93.52M | -15.7M | -200.17M | -18.36M | -85.12M |
| Change in Receivables | 0 | 0 | 0 | 0 | -10.1M | 2.38M | 0 | -58.48M | -101.28M |
| Change in Inventory | 0 | 0 | 0 | 0 | -16.32M | -69.4M | 0 | -10.76M | -15.27M |
| Change in Payables | 932.3K | 6.59M | -1.64M | -54K | 10.49M | 18.69M | 170K | 1.09M | 18.22M |
| Cash from Investing | 0 | 0 | -1.69M | -316.99M | 247.62M | 59.89M | -674K | -403K | -313K |
| Capital Expenditures | 0 | 0 | -1.69M | -5.42M | -1.1M | -1.52M | -773K | -403K | -313K |
| CapEx % of Revenue | - | - | - | 2.16% | 1.66% | 2.02% | 0.19% | 0.05% | 0.03% |
| Acquisitions | 0 | 0 | 0 | 0 | -248.72M | -61.42M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 248.72M | 61.42M | 99K | 0 | 0 |
| Cash from Financing | 197.38M | 131.9M | 388.54M | 692.18M | 392.24M | 365.66M | 394.5M | 149.24M | 8.88M |
| Debt Issued (Net) | 26.36M | 0 | 184.21M | 322.87M | 0 | 0 | 0 | 365.45M | 0 |
| Equity Issued (Net) | 169.81M | 131.19M | 109.58M | 381.42M | 380.36M | 380.12M | 384.39M | 18.83M | 8.89M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.2M | 709.36K | 94.75M | -12.12M | 11.87M | -14.46M | 10.11M | -235.04M | -11K |
| Net Change in Cash | 150.78M▲ 0% | 624.14K▼ 99.6% | 175.72M▲ 28053.6% | 215.06M▲ 22.4% | 74.71M▼ 65.3% | -88.68M▼ 218.7% | -200.78M▼ 126.4% | 60.31M▲ 130.0% | 55.15M▼ 8.6% |
| Free Cash Flow | -46.6M▲ 0% | -131.24M▼ 181.7% | -212.83M▼ 62.2% | -165.91M▲ 22.0% | -564.23M▼ 240.1% | -515.27M▲ 8.7% | -595.51M▼ 15.6% | -88.27M▲ 85.2% | 45.01M▲ 151.0% |
| FCF Margin % | - | - | - | -66.19% | -847.66% | -683.18% | -150.16% | -11.3% | 4.48% |
| FCF Growth % | -79.19% | -181.66% | -62.17% | 22.05% | -240.08% | 8.68% | -15.57% | 85.18% | 151% |
| FCF per Share | -1.36 | -2.41 | -3.42 | -2.21 | -6.68 | -4.86 | -5.02 | -0.71 | 0.36 |
| FCF Conversion (FCF/Net Income) | 0.91x | 1.03x | 0.69x | 0.47x | 0.75x | 0.79x | 1.13x | 0.44x | 2.02x |
| Interest Paid | 0 | 0 | 987K | 12.93M | 10.27M | 5M | 0 | 29.37M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 49K | 4.92M | 0 | 1.65M | 0 |
APLS Key Ratios
Apellis Pharmaceuticals, Inc. (APLS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -92.31% | -59.06% | -82.28% | -312.2% | -288.86% | -370.2% | -353.93% | -290.14% | -93.55% | 7.48% |
| Return on Invested Capital (ROIC) | - | - | -1677.51% | - | -970.89% | - | - | - | -102.56% | 12.3% |
| Gross Margin | - | - | - | - | 90.01% | 92.19% | 92.53% | 85.25% | 84.93% | 89.81% |
| Net Margin | - | - | - | - | -137.59% | -1121.27% | -864.7% | -133.29% | -25.32% | 2.23% |
| Debt / Equity | - | 0.18x | 0.17x | 4.59x | 1.85x | 1.06x | 0.66x | 0.57x | 2.06x | 1.31x |
| Interest Coverage | - | -525.30x | -49.74x | -56.66x | -10.46x | -55.34x | -18.97x | -16.80x | -3.87x | 1.54x |
| FCF Conversion | 0.96x | 0.91x | 1.03x | 0.69x | 0.47x | 0.75x | 0.79x | 1.13x | 0.44x | 2.02x |
| Revenue Growth | - | - | - | - | - | -73.44% | 13.31% | 425.83% | 97.02% | 28.46% |
APLS SEC Filings & Documents
Apellis Pharmaceuticals, Inc. (APLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
APLS Frequently Asked Questions
Apellis Pharmaceuticals, Inc. (APLS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Apellis Pharmaceuticals, Inc. (APLS) reported $1.00B in revenue for fiscal year 2025.
Apellis Pharmaceuticals, Inc. (APLS) grew revenue by 28.5% over the past year. This is strong growth.
Yes, Apellis Pharmaceuticals, Inc. (APLS) is profitable, generating $22.4M in net income for fiscal year 2025 (2.2% net margin).
Dividend & Returns
Apellis Pharmaceuticals, Inc. (APLS) has a return on equity (ROE) of 7.5%. This is below average, suggesting room for improvement.
Apellis Pharmaceuticals, Inc. (APLS) generated $45.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More APLS
Apellis Pharmaceuticals, Inc. (APLS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates